PARP1 and ovarian carcinoma: Many PARP1 inhibitors have been approved for treatment of human malignancies or under clinical investigation, such as olaparib (AZD2281), veliparib (ABT-888), and rucaparib (AG-014699, PF-01367338), for treatment of ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and unspecified solid tumors [1,2,3].